IPCALAB - Technical Analysis with Chart Patterns & Indicators

Last Updated Time : 19 Sept 25, 2:16 pm

Technical Rating: 3.6

Here’s a detailed technical analysis of IPCA Laboratories Ltd (IPCALAB)

📊 Trend Overview

Phase: Reversing with bearish undertone

Price Action: Trading below both 50-DMA (₹1,377) and 200-DMA (₹1,405), indicating short-term weakness and lack of bullish confirmation.

Volume: Slightly above average (1.74L vs 1.52L), suggesting active trading but not breakout-level enthusiasm.

📈 Momentum Indicators

RSI (45.7): Weak zone — momentum is softening, approaching oversold territory.

MACD (-23.7): Deeply negative — confirms bearish momentum and trend continuation.

Bollinger Bands: Price likely near the lower band, indicating oversold conditions and potential for a technical bounce.

🧭 Chart Patterns

Descending Channel: Price has been declining from ₹1,758, forming lower highs and lower lows.

Base Formation Attempt: Stabilization near ₹1,300–₹1,340 zone suggests potential bottoming, but confirmation is lacking.

🔍 Support & Resistance Levels

Level Price (₹) Commentary

Support 1 1,300 Minor pullback zone

Support 2 1,250 Previous swing low

Support 3 1,168 52-week low

Resistance 1 1,377 50-DMA, short-term ceiling

Resistance 2 1,405 200-DMA, trend reversal trigger

Major Resistance 1,550–1,758 Breakdown zone and 52-week high

🎯 Entry & Exit Zones

Optimal Entry: ₹1,300–₹1,341 (on dips with reversal confirmation)

Short-Term Target: ₹1,377–₹1,405

Exit Zone / Stop-Loss: ₹1,250 (below swing support)

🔄 Short-Term Outlook

Momentum: Weak and declining

Bias: Bearish below ₹1,377; neutral-to-bullish only above ₹1,405

Phase: Reversing — early signs of base formation but no breakout yet

🧠 Key Takeaways

IPCALAB is showing signs of short-term weakness despite strong quarterly profit growth.

RSI and MACD confirm bearish momentum, while price action suggests a possible retest of support near ₹1,300.

A close above ₹1,377 with volume could revive bullish sentiment and open upside toward ₹1,405–₹1,550.

Let me know if you’d like a chart visualization or screener of similar pharma sector reversal setups.

Edit in a page